Signos Company Overview: Business Model, CGM Science, and Independent Analysis

What Signos Actually Sells

Signos bundles three components into a single monthly subscription: a prescription CGM sensor, access to a mobile application with AI-generated meal and exercise recommendations, and periodic telehealth check-ins. The CGM itself is not a Signos product. It is a Dexcom G7 or Abbott FreeStyle Libre 3, both FDA-cleared devices originally designed for diabetes management. Signos adds a software layer that interprets glucose data and translates spikes into dietary coaching signals.

The subscription model works like this. A licensed clinician on the Signos network writes an off-label prescription for a CGM. The patient receives sensors by mail, applies them to the upper arm or abdomen, and syncs readings to the Signos app. The app scores meals, flags glucose spikes, and recommends exercise timing. Some higher-tier plans now include evaluation for GLP-1 receptor agonist prescriptions like semaglutide or tirzepatide, though this appears to be a more recent addition to the product line.

Revenue comes from recurring subscriptions rather than insurance reimbursement, since most insurers do not cover CGMs for non-diabetic patients. This positions Signos as a cash-pay wellness service, not a medical device company.

The Science Behind CGM-Guided Weight Loss

Continuous glucose monitoring has strong clinical evidence in diabetes. That much is clear. A 2017 meta-analysis published in JAMA found that CGM use in type 1 diabetes reduced HbA1c by 0.3% compared to self-monitoring of blood glucose (1). The American Diabetes Association's 2024 Standards of Care recommends CGM for all adults with type 1 diabetes and many with type 2 diabetes on insulin therapy.

The question is whether this technology translates to weight loss in people without diabetes. The evidence here is thin. A 2023 pilot study in Obesity (N=59) examined CGM-guided dietary interventions in adults with overweight or obesity but without diabetes. Participants using CGM lost a mean of 3.1 kg over 12 weeks compared to 1.8 kg in controls, but the study was not powered for statistical significance on weight outcomes (2).

Glucose variability itself may play a role in appetite regulation. Research published in Nature Metabolism (2021) demonstrated that large postprandial glucose dips predicted greater hunger and increased caloric intake in the subsequent meal in a cohort of 1,070 participants (3). This supports the theoretical basis for CGM-guided eating. If you can see which foods cause steep glucose drops, you might make choices that reduce hunger.

But theory is not proof. No large RCT has demonstrated that wearing a CGM produces clinically meaningful weight loss (defined as 5% or more of body weight) in non-diabetic adults over 6 to 12 months. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy does not mention CGM as a weight management tool.

Signos Pricing and Plan Structure

Signos uses a tiered pricing model that rewards longer commitments. As of early 2026, the approximate costs break down as follows: a month-to-month plan runs about $399 per month, a 3-month plan drops to roughly $299 per month, and a 6-month or 12-month plan brings the price to around $199 per month. These prices include the CGM sensors, app access, and telehealth consultations. They do not include prescription medications if a clinician determines GLP-1 therapy is appropriate.

For comparison, a box of two Dexcom G7 sensors (covering 20 days) retails for approximately $150 to $200 without insurance. The Signos markup covers the app, AI analysis, telehealth visits, and the off-label prescription facilitation. Whether that markup delivers value depends on how much actionable behavior change the app produces for a given user.

There is no published retention data from Signos, and the company has not disclosed average subscriber duration. This matters. Weight management interventions that produce short-term engagement but high churn rates tend to have poor long-term outcomes. The U.S. Preventive Services Task Force recommends behavioral interventions of 12 or more contact sessions over at least 12 months for meaningful weight outcomes, a duration that exceeds most consumers' tolerance for a $200-plus monthly subscription.

Is Signos Legit?

Signos is a real company with real clinicians writing real prescriptions. It is not a scam in the conventional sense. The CGM hardware is FDA-cleared, the telehealth model operates within state medical board regulations, and the app delivers genuine glucose data. The more relevant question is whether CGM data produces better weight-loss outcomes than simpler, cheaper alternatives.

A 2022 systematic review in Diabetes Technology & Therapeutics evaluated CGM use in non-diabetic populations and concluded that while the devices accurately measure glucose, "evidence for clinical benefit in weight management remains insufficient to support routine use" (4). Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "CGMs are incredibly valuable for people with diabetes, but we need more data before we can say they're effective tools for weight loss in the general population" (5).

The legitimacy concern is not fraud. It is premature commercialization of a technology whose weight-loss applications lack the evidence base that its diabetes applications enjoy. Signos markets a sophisticated experience, but the clinical question of whether seeing your glucose after a bagel translates into sustained weight loss remains open.

Signos vs. Alternatives

Several companies compete in the consumer CGM space. Nutrisense, Levels Health (which paused consumer operations in 2023 before pivoting), Veri, and January AI all use similar models: off-label CGM prescription plus app-based coaching. Pricing across these services falls in a comparable range of $150 to $400 per month.

The differentiation between these platforms is almost entirely in software. They all use the same two CGM sensors (Dexcom G7 or FreeStyle Libre 3). The difference comes down to how the app interprets data, what kind of coaching it provides, and whether it integrates additional services like dietitian access or medication management.

Signos distinguishes itself by incorporating GLP-1 prescribing into some plans. This is a meaningful differentiator. GLP-1 receptor agonists have the strongest evidence base of any obesity pharmacotherapy. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) (6). Tirzepatide 15 mg (Zepbound) produced 22.5% weight loss at 72 weeks in SURMOUNT-1 (N=2,539) (7).

If a Signos subscription leads to a GLP-1 prescription for an appropriate candidate, the CGM component may serve as a useful biofeedback layer alongside proven pharmacotherapy. Without the medication component, the evidence for CGM alone driving weight loss is limited. A non-CGM alternative worth considering: the Diabetes Prevention Program (DPP) is a structured behavioral intervention covered by many insurers that produced 5.6% mean weight loss at one year in the original NIH trial (8).

Who Might Benefit from Signos

Not every consumer fits the Signos use case. The strongest candidates are those with prediabetes (fasting glucose 100-125 mg/dL or HbA1c 5.7-6.4%), where CGM data can provide genuinely actionable insights. The CDC estimates that 97.6 million U.S. adults aged 18 and older have prediabetes (9). For this group, real-time glucose feedback could support the dietary modifications that delay or prevent progression to type 2 diabetes.

For metabolically healthy individuals with a BMI of 25 to 30 who simply want to lose 10 to 15 pounds, the cost-benefit calculation is harder to justify. These individuals typically have normal glucose responses, and seeing flat glucose curves after meals may not provide the behavioral nudges that the marketing implies.

Dr. Anne Peters, Professor of Medicine at the Keck School of Medicine at USC, has noted: "In my clinical experience, CGM can be eye-opening for patients who don't realize how their food choices affect blood sugar, but the people who benefit most already have some degree of glucose dysregulation" (10).

A practical framework for deciding: if your fasting glucose is above 100 mg/dL, your HbA1c sits between 5.7% and 6.4%, or you have a family history of type 2 diabetes and want granular dietary feedback, a 3-month CGM trial (through Signos or any competing platform) may provide useful data. If your metabolic markers are normal and your primary goal is weight loss, the $600 to $1,200 you would spend on a 3-month Signos plan might produce better results if redirected toward a registered dietitian, a structured exercise program, or evaluation for GLP-1 pharmacotherapy with a physician.

Red Flags and Limitations

Several aspects of the Signos model deserve scrutiny. First, the off-label prescription pathway. CGMs are FDA-cleared for glucose monitoring, not for weight loss coaching. Off-label prescribing is legal and common in medicine, but consumers should understand that the FDA has not evaluated CGM use for weight management specifically.

Second, the data privacy dimension. Signos collects continuous biometric data, dietary logs, and exercise information. The company's privacy policy should be reviewed carefully. Glucose data is health information, and consumers should understand how it is stored, shared, and potentially monetized.

Third, subscription fatigue and long-term adherence. A 2021 study in the Journal of Medical Internet Research found that engagement with digital health apps declines by approximately 50% after 30 days (11). At $200 to $400 per month, low engagement represents a significant financial cost for minimal clinical benefit.

Fourth, the absence of published outcomes data from Signos itself. As of this writing, Signos has not published peer-reviewed studies demonstrating weight-loss outcomes in its user population. Companies making health claims bear a responsibility to generate and share outcomes data. Without it, consumers are relying on the general CGM literature (which, as discussed, is limited for weight loss in non-diabetic populations) and testimonials.

The Bottom Line on Signos as a Business

Signos occupies a growing niche in consumer health technology: applying medical-grade devices to wellness-oriented populations willing to pay out of pocket. The business model is subscription-driven, dependent on consumer engagement and perception of value rather than clinical outcomes data or insurance reimbursement.

The CGM technology itself is validated. The application of that technology to weight loss in non-diabetic adults is not yet supported by the kind of evidence that the medical community typically requires before recommending an intervention. Signos may be most useful for individuals with prediabetes or insulin resistance who want real-time feedback on dietary choices, and least useful for metabolically healthy individuals who could achieve similar weight-loss results through less expensive behavioral or pharmacologic interventions.

If you are considering Signos, discuss CGM monitoring with your physician first. A fasting glucose test and HbA1c measurement (typically $15 to $30 through most labs) can help determine whether real-time glucose data is likely to tell you something you do not already know.